|
|
|
| The Curative Effect of Cilazapril Combined with Isosorbide Mononitrate on COPD and Heart Failure and The Influences on Serum Cardiopulmonary Function Indexes and Inflammatory Factors |
| LIN Dandan, ZHOU Yan, et al |
| The First Affiliated Hospital of Army Military Medical University, Chongqing 400038, China |
|
|
|
|
Abstract Objective: To explore clinical curative effect of cilazapril combined with isosorbide mononitrate on COPD and heart failure and their influences on serum cardiopulmonary function and inflammatory factors. Methods: A total of 150 patients with COPD and heart failure who were admitted to the hospital from May 2017 to March 2018 were enrolled. They were divided into observation group (n=75) and control group (n=75) by simple random grouping method. The control group was treated with isosorbide mononitrate, while observation group was additionally treated with cilazapril. The clinical curative effect, cardiopulmonary function and inflammatory factors indexes were compared between the two groups. Result: The total response rate of clinical curative effect in observation group was higher than that in control group (90.67% vs 78.67%) (P<0.05). Before treatment, there were no statistical differences in cardiac function, pulmonary function and inflammatory factors indexes between the two groups (P>0.05). After treatment, levels of LVEF, FVC, FEV1 and FEV1/FVC in observation group were higher than those in control group (P<0.05), while levels of LVEDD, BNP, hs-CRP, serum IL-6, IL-8 and TNF-α were lower than those in control group (P<0.05). Conclusion: The curative effect of cilazapril combined with isosorbide mononitrate is significant on COPD combined with heart failure. It can improve response rate of treatment, clinical symptoms and cardiopulmonary function, down-regulate expression of inflammatory factors, and reduce inflammatory response.
|
|
|
|
|
|
[1] 刘旭.慢性阻塞性肺病合并糖尿病中皮质类固醇的使用对糖尿病并发症的影响[J].基因组学与应用生物学,2019,38(11):5204~5208.
[2] 王海丽,周剑平,孟俊,等.慢性阻塞性肺病患者红细胞分布宽度与右心衰竭的相关性研究[J].上海交通大学学报,2018,38(6):115~117.
[3] 方秀珍,刘溢雯,付美芳,等.单硝酸异山梨酯治疗N端脑钠肽异常的慢性阻塞性肺疾病的临床效果[J].中国当代医药,2019,26(8):41~43,47.
[4] 唐清娥.西拉普利联合单硝酸异山梨酯对肺心病合并心力衰竭的治疗效果[J].中华心脏与心律电子杂志,2019,7(2):80~82.
[5] 邱佰云,俞今晶.肺康复在COPD及慢性呼吸系统疾病中的作用及实施[J].中国医疗设备,2018,33(S2):102~104.
[6] 叶任高,陆再英.内科学[M].第6版.北京:人民卫生出版社,2004.156~158.
[7] Liao KM,Lin TY,Huang YB,et al. The evaluation of β-adrenoceptor blocking agents in patients with COPD and congestive heart failure: a nationwide study[J]. Int Chron Obstruct Pulmon Dis,2017,12(26):2573~2581.
[8] 刘军.BiPAP呼吸机治疗COPD急性加重期合并急性左心衰临床分析[J].中国医疗器械信息,2017,23(12):59~60.
[9] 李艳,刘宇.合并COPD心衰患者比索洛尔的应用[J].泰山医学院学报,2017,38(2):160~162. |
|
|
|
2020, Vol. 26 
